Clinical Trials
4 trialsNCT06625515 2026-02-24
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Phase 1 Terminated
NCT03594448 2024-08-29
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
University of Southern California
Terminated
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT03827044 2022-10-07
POLEM
Royal Marsden NHS Foundation Trust
Phase 3 Terminated